Topline results from the Phase 2 CELIA study of Diranersen (BIIB080) in early stage Alzheimer's disease announced at AAIC.

See link: https://investors.biogen.com/news-releases/news-release-details/biogen-presents-phase-2-celia-data-aaic-demonstrating-meaningful